Blood Cancer Treatment Awakens "Sleeping" Cancer Gene - Technology Networks

In a recent study, hypomethylating agents used to treat myelodysplastic syndrome have been shown to activate the oncogenic protein SALL4, leading to poor survival outcomes in patients.

Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS) - a group of disorders where there is insufficient production of healthy mat… [+3658 chars]

full article...